KOD

+ Watchlist + Portfolio

Kodiak Sciences Inc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $40.07
52-Week Range: $8.29 – $47.84
Market Cap: $2.50B
P/E (TTM): —
EPS (TTM): -4.19
Dividend Yield: —

Advanced Metrics

Price/Book: 40.90
PEG Ratio: —
Return on Equity: -368.37%
Return on Assets: -60.45%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.49
Debt/Equity: 0.86
Total Debt: $52.76M
Free Cash Flow: $-58.39M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.44B

KOD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$267.59M	$206.30M	$126.09M	$182.37M
Selling, General & Admin	$73.79M	$71.02M	$60.75M	$52.02M
Operating Expenses	$341.38M	$277.32M	$186.85M	$234.39M
Operating Income	-$341.38M	-$277.32M	-$186.85M	-$234.39M
EBITDA	-$322.80M	-$234.53M	-$149.50M	-$203.65M
Pretax Income	-$333.82M	-$260.49M	-$176.21M	-$229.97M
Net Income	-$333.82M	-$260.49M	-$176.21M	-$229.97M
Diluted EPS	-6.39	-4.97	-3.35	-4.32
Diluted Shares	52.25M	52.41M	52.58M	53.21M

KOD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$190.43M	$285.51M	$168.07M	$209.86M
Current Assets	$486.00M	$289.31M	$171.94M	$214.82M
Total Assets	$666.63M	$479.37M	$335.58M	$351.53M
Current Liabilities	$52.50M	$41.73M	$25.57M	$45.53M
Total Debt	$87.73M	$81.63M	$70.34M	$59.18M
Total Liabilities	$230.46M	$213.59M	$185.29M	$194.15M
Retained Earnings	-$892.04M	-$1.15B	-$1.33B	-$1.56B
Shareholders' Equity	$436.17M	$265.78M	$150.29M	$157.38M
Working Capital	$433.51M	$247.58M	$146.36M	$169.28M

KOD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$206.46M	-$154.18M	-$117.32M	-$136.01M
Capital Expenditure	-$47.36M	-$41.43M	-$400.00K	-$506.00K
Free Cash Flow	-$253.82M	-$195.61M	-$117.72M	-$136.51M
Depreciation & Amortisation	$11.00M	$25.95M	$26.71M	$26.32M
Stock-Based Compensation	$106.03M	$88.56M	$60.21M	$58.86M
Investing Cash Flow	-$336.51M	$249.23M	-$755.00K	-$506.00K
Financing Cash Flow	$1.90M	$31.00K	$501.00K	$178.30M
Share Repurchases	$0.00	—	—	—
Net Change in Cash	-$541.08M	$95.07M	-$117.57M	$41.79M

KOD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$43.64M	$42.76M	$50.48M	$45.49M	$48.55M
Selling, General & Admin	$15.43M	$12.75M	$11.88M	$11.96M	$11.23M
Operating Expenses	$59.07M	$55.51M	$62.35M	$57.45M	$59.78M
Operating Income	-$59.07M	-$55.51M	-$62.35M	-$57.45M	-$59.78M
EBITDA	-$52.34M	-$48.97M	-$55.81M	-$46.52M	-$53.44M
Pretax Income	-$57.46M	-$54.31M	-$61.46M	-$56.74M	-$58.16M
Net Income	-$57.46M	-$54.31M	-$61.46M	-$56.74M	-$58.16M
Diluted EPS	-1.09	-1.03	-1.16	-1.04	-0.94
Diluted Shares	52.75M	52.78M	52.86M	54.43M	61.86M

KOD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$138.85M	$104.17M	$72.04M	$209.86M	$169.53M
Current Assets	$142.69M	$107.92M	$75.73M	$214.82M	$175.26M
Total Assets	$297.91M	$256.73M	$218.07M	$351.53M	$306.01M
Current Liabilities	$30.88M	$31.01M	$42.43M	$45.53M	$49.57M
Total Debt	$67.64M	$65.21M	$62.20M	$59.18M	$55.99M
Total Liabilities	$189.07M	$186.44M	$194.38M	$194.15M	$193.91M
Retained Earnings	-$1.39B	-$1.44B	-$1.50B	-$1.56B	-$1.62B
Shareholders' Equity	$108.84M	$70.29M	$23.69M	$157.38M	$112.10M
Working Capital	$111.81M	$76.91M	$33.30M	$169.28M	$125.69M

KOD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$29.08M	-$34.67M	-$32.88M	-$39.38M	-$40.01M
Capital Expenditure	-$270.00K	-$133.00K	-$60.00K	-$43.00K	-$942.00K
Free Cash Flow	-$29.35M	-$34.81M	-$32.94M	-$39.42M	-$40.95M
Depreciation & Amortisation	$6.73M	$6.54M	$6.54M	$6.51M	$6.34M
Stock-Based Compensation	$15.89M	$15.64M	$14.05M	$13.29M	$12.15M
Investing Cash Flow	-$270.00K	-$133.00K	-$60.00K	-$43.00K	-$942.00K
Financing Cash Flow	$124.00K	$120.00K	$813.00K	$177.25M	$619.00K
Net Change in Cash	-$29.22M	-$34.69M	-$32.13M	$137.82M	-$40.33M

Market Snapshot

About

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic retinal diseases. The company's proprietary platform focuses on developing longer-lasting treatments for conditions like wet age-related macular degeneration and diabetic retinopathy. Kodiak's lead product candidate is designed to reduce treatment burden through extended dosing intervals.